Basic HTML Version
© The Canadian Journal of Urology™; 18(Supplement 1); April 2011
46. Abrams P, Blaivas JG, Stanton SL, Andersen JT. The
standardisation of terminology of lower urinary tract
function. The International Continence Society Committee
on Standardisation of Terminology.
Scand J Urol Nephrol Suppl
1988;114:5-19.
47. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and
burden of overactive bladder in the United States.
World J Urol
2003;20(6):327-336.
48. Hannestad YS, Rortveit G, Sandvik H, Hunskaar S. A
community-based epidemiological survey of female urinary
incontinence: the Norwegian EPINCONT study. Epidemiology
of Incontinence in the County of Nord-Trondelag.
J Clin Epidemiol
2000;53(11):1150-1157.
49. Corcos J, Schick E. Prevalence of overactive bladder and
incontinence in Canada.
Can J Urol
2004;11(3):2278-2284.
50. Hu TW, Wagner TH, Bentkover JD et al. Estimated economic
costs of overactive bladder in the United States.
Urology
2003;61(6):1123-1128.
51. Langa KM, Fultz NH, Saint S, KabetoMU, HerzogAR. Informal
caregiving time and costs for urinary incontinence in older
individuals in the United States.
J AmGeriatr Soc
2002;50(4):733-
737.
52. Jackson S. The patient with an overactive bladder--symptoms
and quality-of-life issues.
Urology
1997;50(6A Suppl):18-
22;discussion 23-14.
53. ThomDH, HaanMN, Van Den Eeden SK. Medically recognized
urinary incontinence and risks of hospitalization, nursing home
admission and mortality.
Age Aging
1997;26(5):367-374.
54. Scarpero HM, Dmochowski RR. Muscarinic receptors: what we
know.
Curr Urol Rep
2003;4(6):421-428.
55. Staskin DR, Robinson D.Oxybutynin chloride topical gel: a
new formulation of an established antimuscarinic therapy for
overactive bladder.
Expert Opin Pharmacother
2009;10(18):3103-
3111.
56. Sand PK. The evolution of transdermal therapy for overactive
bladder.
Current Urol Reports
2009;10:338-341.
57. Chu FM, Dmochowski RR, Lama DJ, Anderson RU, Sand PK.
Extended-release formulations of oxybutynin and tolterodine
exhibit similar central nervous system tolerability profiles: a
subanalysis of data from the OPERA trial.
Am J Obstet Gynecol
2005;192(6):1849-1854.
58. Doroshyenko O, Jetter A, Odenthal KP, Fuhr U. Clinical
pharmacokinetics of trospium chloride.
Clin Pharmacokinet
2005;44(7):701-720.
59. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective
receptor antagonist, is an effective andwell-tolerated once-daily
treatment for overactive bladder.
Eur Urol
2004;45(4):420-429.
60. Cardozo L, Lisec M, Millard R et al. Randomized, double-blind
placebo controlled trial of the once daily antimuscarinic agent
solifenacin succinate in patients with overactive bladder.
J Urol
2004;172(5 Pt 1):1919-1924.
61.
Nitti VW, Dmochowski R, Sand PK et al. Efficacy, safety and
tolerability of fesoterodine for overactive bladder syndrome.
J Urol
2007;178(6):2488-2494.
62. Sand PK, Morrow JD, Bavendam T, Creanga DL, Nitti VW.
Efficacy and tolerability of fesoterodine inwomenwith overactive
bladder.
Int Urogynecol J Pelvic Floor Dysfunct
2009;20(7):827-835.
63. Guay DR. Clinical pharmacokinetics of drugs used to treat urge
incontinence.
Clin Pharmacokinet
2003;42:1243-1285.
64. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy
for prostate cancer.
JAMA
2005;294(2):238-244.
65. Pinthus JH. Androgen deprivation therapy for prostate cancer.
AUA Update Series
2006;25(Lesson 15):134-139.
66. Gomella LG. Effective testosterone suppression for prostate
cancer: is there a best castration therapy?
RevUrol
2009;11(2):52-60.
67. Gomella LG, Johannes J, Trabulsi EJ. Current prostate
cancer treatments: effect on quality of life.
Urology
2009;73(5
Suppl):S28-S35.
68. Saad F, Abrahamsson PA, Miller K. Preserving bone health in
patients with hormone-sensitive prostate cancer: the role of
bisphosphonates.
BJU Int
2009;104(11):1573-1579.
69. Lau YK, Lee E, Prior HJ, Lix LM, Metge CJ, Leslie WD. Fracture
risk in androgen deprivation therapy: a Canadian population
based analysis.
Can J Urol
2009;16(6):4908-4914.
70. Saad F, Gleason DM, Murray R et al. A randomized, placebo-
controlled trial of zoledronic acid in patients with hormone-
refractory metastatic prostate carcinoma.
J Natl Cancer Inst
2002;94(19):1458-1468.
71. Silver DA. Denosumab reduces the incidence of new vertebral
fractures in men with prostate cancer.
Curr Osteoporos Rep
2010;8(1):1-3.
72. Fizazi K, Carducci M, Smith M et al. Denosumab versus
zoledronic acid for treatment of bone metastases in men with
castration-resistant prostate cancer: a randomized, double-blind
study.
Lancet
2011;377:813-822.
73. Chodak G, Gomella L, Phung de H. Combined androgen
blockade in advanced prostate cancer: looking back to move
forward.
Clin Genitourin Cancer
2007;5(6):371-378.
74. Baltogiannis D, Giannakopoulos X, Charalabopoulos K, Sofikitis
N. Monotherapy in advanced prostate cancer: an overview.
Exp
Oncol
2004;26(3):185-191.
75. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor
pathway in prostate cancer.
Curr Opin Pharmacol
2008;8(4):440-
448.
76. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and
estramustine compared with mitoxantrone and prednisone
for advanced refractory prostate cancer.
N Engl J Med
2004;351(15):1513-1520.
77. Tannock IF, de Wit R, Berry WR et al. TAX 327 Investigators.
Docetaxel plus prednisone or mitoxantrone plus prednisone for
advanced prostate cancer.
N Engl J Med
2004;351(15):1502-1512.
78. Kantoff PW, Higano CS, Shore ND et al. IMPACT Study
Investigators. Sipuleucel-T immunotherapy for castration-
resistant prostate cancer.
N Engl J Med
2010;363(5):411-422.
38
LIU ET AL.